< Back to search
Filter
1

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

for
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Location: Philadelphia PA
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07463807

Phase1, Phase2, Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

for
Relapsed or Refractory Multiple Myeloma
Location: Boston MA, New York NY, Philadelphia PA, Charlotte NC,
Sponsor: ModernaTX, Inc.

Sex: All

Age: 18+

Code: NCT07116616

Phase1, Phase2, Recruiting

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

for
Multiple Myeloma
Location: Miami FL
Sponsor: University of Miami

Sex: All

Age: 18+

Code: NCT06997081

Phase2, Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Halifax, New Haven CT, Hackensack NJ, Toronto,
Sponsor: Celgene

Sex: All

Age: 18+

Code: NCT06988488

Phase1, Phase2, Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

for
Multiple Myeloma
Location: Boston MA, Durham NC, Seattle WA
Sponsor: Karyopharm Therapeutics Inc

Sex: All

Age: 18+

Code: NCT02343042

Phase1, Phase2, Recruiting

Interested in new multiple sclerosis trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

for
Multiple Myeloma, Multiple Myeloma Progression,
Location: Charlotte NC
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 30+

Code: NCT06644625

Recruiting

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

for
Multiple System Atrophy
Location: Boston MA
Sponsor: Tiziana Life Sciences LTD

Sex: All

Age: 30 - 70+

Code: NCT06868628

Phase2, Recruiting

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

for
High Risk Smoldering Multiple Myeloma (HR-SMM)
Location: Boston MA, Detroit MI, Atlanta GA
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07393282

Phase3, Recruiting

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

for
Multiple Myeloma, Multiple Myeloma in Relapse,
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT07200089

Phase1, Recruiting

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

for
Multiple Myeloma (MM)
Location: Tamarac FL, Plantation FL, Margate FL, Jacksonville FL,
Sponsor: Shanghai Henlius Biotech

Sex: All

Age: 18+

Code: NCT07477587

Phase1, Recruiting

Horizon Two: HR NDMM (MMRC-100)

for
High Risk Newly Diagnosed Multiple Myeloma
Location: New York NY, Chapel Hill NC, Detroit MI, Atlanta GA,
Sponsor: Multiple Myeloma Research Consortium

Sex: All

Age: 18+

Code: NCT07053436

Phase2, Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

for
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Location: Madison WI
Sponsor: Natalie Callander

Sex: All

Age: 18+

Code: NCT07479979

Phase1, Phase2, Recruiting

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma, Relapse Multiple Myeloma,
Location: Boston MA
Sponsor: David Avigan

Sex: All

Age: 18+

Code: NCT06799026

Phase1, Recruiting

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

for
Multiple Myeloma, Post Stem Cell Transplant
Location: Palo Alto CA
Sponsor: Stanford University

Sex: All

Age: 18+

Code: NCT06461988

Phase2, Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Boston MA, Hackensack NJ, New Brunswick NJ,
Sponsor: CellCentric Ltd.

Sex: All

Age: 18+

Code: NCT07096778

Phase2, Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

for
Multiple Myeloma
Location: Halifax, Commack NY, Uniondale NY, Harrison NY,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT05020236

Phase3, Recruiting

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Location: New York NY, Columbus OH, Atlanta GA, Houston TX
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07222761

Phase3, Recruiting

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

for
Multiple Myeloma
Location: New Haven CT
Sponsor: Noffar Bar

Sex: All

Age: 18+

Code: NCT06993675

Phase2, Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

for
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Location: Norfolk VA, Chapel Hill NC, Columbus OH, Birmingham AL,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 19+

Code: NCT06974786

Phase2, Recruiting

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

for
Hypothalamic Obesity,
Location: Boston MA, New York NY, Philadelphia PA, Birmingham AL,
Sponsor: Rhythm Pharmaceuticals, Inc.

Sex: All

Age: 4+

Code: NCT06760546

Phase3, Recruiting